-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 EQD5dt6pp/JE1RLaZdG8dcSN+3Exf90BXZ5rx+rd4tSFquPCCjkGg4H7manozsPw
 CWB0WJg9hqWE9yx0gKfpzQ==

<SEC-DOCUMENT>0001144204-04-023011.txt : 20041229
<SEC-HEADER>0001144204-04-023011.hdr.sgml : 20041229
<ACCEPTANCE-DATETIME>20041229140205
ACCESSION NUMBER:		0001144204-04-023011
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20041201
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Completion of Acquisition or Disposition of Assets
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20041229
DATE AS OF CHANGE:		20041229

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ADVANCED PLANT PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000943535
		STANDARD INDUSTRIAL CLASSIFICATION:	DAIRY PRODUCTS [2020]
		IRS NUMBER:				592762023
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30256
		FILM NUMBER:		041230560

	BUSINESS ADDRESS:	
		STREET 1:		43 W 33RD STREET
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10001
		BUSINESS PHONE:		2124027878

	MAIL ADDRESS:	
		STREET 1:		43 W 33RD STREET
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10001
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v010547.txt
<TEXT>
                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                     Pursuant to Section 13 OR 15(d) of the
                         Securities Exchange Act of 1934


                        Date of Report: December 1, 2004
                                       ------------------


                      ADVANCED PLANT PHARMACEUTICALS, INC.
             ------------------------------------------------------
             (Exact name of Registrant as Specified in Its Charter)


           Delaware                    000-28459                 59-2762023
- ----------------------------    ------------------------   ------------------
(State or Other Jurisdiction    (Commission File Number)     (IRS Employer
of Incorporation)                                         Identification No.)


                               43 West 33rd Street
                               New York, NY 10001
                   ------------------------------------------
                    (Address of Principal Executive Offices)


       Registrant's telephone number, including area code: (212) 695-3334
                                                           ------------------


           -----------------------------------------------------------
          (Former name or former address, if changes since last report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

|_|   Written communications pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

|_|   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))

<PAGE>


Item 1.01 Entry into a Material Definitive Agreement.
Item 2.01 Completion of Acquisition or Disposition of Assets.

      On December 1, 2004, ADVANCED PLANT PHARMACEUTICALS, INC. (the
"Registrant") entered into an Asset Purchase Agreement (the "Agreement") with
Mazel Plant Pharmaceutical Inc., a Delaware corporation (hereinafter "Mazel") to
sell to Mazel all its rights relating to or connected with developing,
manufacturing and distributing of three of its products, specifically its plant
based compositions designed to treat elevated cholesterol, a plant based
composition designed to treat leukemia and a plant based composition designed to
treat Alzheimer's disease (hereinafter "the Three Pharmaceutical Products"). The
Registrant retained the rights for distributing "LOCHOL" as a nutritional
supplement.

      Under the Agreement the Registrant transferred all Food and Drug
Administration ("FDA") and other United States and foreign governmental drug
safety and efficacy approvals, approvals or licenses of any kind relating to the
Three Pharmaceutical Products, trademarks (either registered or at common),
service marks (either registered or at common), trade names, service names,
labels and copyrights, and all registrations and applications worldwide related
to these Three Pharmaceutical Products, and all technical processes,
compilations, formulations, formulas, recipes and/or other such information
related to or connected with the development, testing, manufacturing, packaging
or repackaging or selling of the Three Pharmaceutical Products which were owned
by the Registrant.

      Under the Agreement, the Registrant received seven million (7,000,000)
shares of common stock of Mazal simultaneously with the execution of the
Agreement. As a result, Mazel became a majority-owned subsidiary of the
Registrant. After the issuance of the shares to the Registrant, Mazal had
7,050,100 shares of common stock issued and outstanding. Mazal is focused on the
FDA development, testing, manufacturing and selling of plant pharmaceutical
drugs.

      In addition under the Agreement, the Registrant shall receive a royalty of
two cents ($0.02) for each bottle of the Three Pharmaceutical Products sold by
Mazel which shall be paid on a quarterly basis. Mazel further agreed to pay
fifty thousand dollars ($50,000) to the Registrant towards the cost of the study
conducted by Clinical Research Laboratories In New Jersey on the effect of
LOCHOL on cholesterol levels.

Item 7.01  Regulation FD Disclosure
<PAGE>

      On December 1, 2004 the Registrant issued a press release announcing that
it has closed an asset sale agreement with Mazal whereby in exchange for
7,000,000 shares of common stock of Mazal, the Registrant transferred
intellectual property to Mazal relating to the Three Pharmaceutical Products
three whole plant pharmaceutical drugs. A copy of the press release is attached
as Exhibit 99.1 to this Form 8-K.

Item 9.01 Financial Statements and Exhibits

          Exhibits:

               Exhibit  No.   Document  Description
               -----------    ---------------------

                     10       Asset Purchase Agreement dated November 24, 2004.

                     99       Press Release dated December 9, 2004.

                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

Dated:  December 28, 2004                  Advanced Plant Pharmaceuticals, Inc.
       -------------------                 ------------------------------------
                                           (Registrant)

                                           By: /s/  David Lieberman
                                              ---------------------------------
                                              David Lieberman

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>2
<FILENAME>v010547_ex10.txt
<TEXT>
Exhibit 10 - Asset Purchase Agreement

                            ASSET PURCHASE AGREEMENT

 ASSET PURCHASE AGREEMENT, made as of December 1, 2004, by and between Advanced
 Plant Pharmaceuticals, Inc., a Delaware Corporation, with principal offices at
 43 West 33rd Street, New York, New York 10001 (hereinafter referred to as the
 "Seller") and Mazal Plant Pharmaceutical Inc., a Delaware Corporation, with
 principal offices at 43 west 33rd Street N.Y N.Y (hereinafter referred to as
 the "Purchaser").

                                   WITNESSETH:

 WHEREAS, the Purchaser is engaged in the business of developing, testing,
 manufacturing and selling plant based pharmaceuticals, and is desirous of
 purchasing assets which pertains to the business of the Purchaser;

 WHEREAS, the Seller has developed plant based compositions designed to treat
 elevated cholesterol, a plant based composition designed to treat leukemia and
 a plant based composition designed to treat Alzheimer's disease (hereinafter
 referred as "Three Pharmaceuticals"). The Seller has also developed a method
 for producing said plant compositions into a drug form;

 WHEREAS, the Purchaser is desirous of manufacturing, distributing and selling
 the above THREE PHARMACEUTICALS in any country where it is approved for sale by
 the respective governmental drug and other regulatory agencies;

 NOW, THEREFORE, in consideration of the covenants and agreements hereafter set
 forth, and other valuable consideration, the receipt, and sufficiency of which
 hereby are acknowledged, the parties hereto agree as follows:

                                    ARTICLE 1

                           PURCHASE AND SALE OF ASSET

1.1 Purchase and Sale. Subject to the provisions of this Agreement, the Seller
shall sell, convey, transfer, assign and deliver to Purchaser, by appropriate
instruments in form satisfactory to Purchaser, and Purchaser shall purchase and
accept, for the consideration hereinafter provided, above THREE PHARMACEUTICALS
and the appurtenant property rights of the Seller described herein, specifically
including, but without Limitation, the following:

(a) all rights owned, held or enjoyed by the Seller relating to or connected
with developing, manufacturing and distributing above THREE PHARMACEUTICALS as
pharmaceutical drugs (specifically, the rights for distributing "LOCHOL" as a
nutritional supplement remain with the seller) including, but not be limited to,
the complete underlying dossier and supporting documentation, studies and tests,
formulations, manufacturing processes, drug delivery methodologies and technical
processes;

(b) all patents, Food and Drug Administration ("FDA") and other United States
and foreign governmental drug safety and efficacy approvals, approvals or
licenses of any kind relating to above THREE PHARMACEUTICALS, trademarks (either
registered or at common), service marks (either registered or at common) trade
names, service names, labels and copyrights, and all registrations and
applications worldwide related to above THREE PHARMACEUTICALS, and all technical
processes, compilations, formulations, formulas, recipes and/or other such
information related to or connected with the development, testing,
manufacturing, packaging or repackaging or selling of above THREE
PHARMACEUTICALS which is owned by the Seller (collectively hereinafter referred
to as "Intellectual Property Rights");
<PAGE>

(c) copies of all books and records of the Seller relating to studies, trade
secrets, technical information, development, manufacture, distribution and
goodwill, if any, of above THREE PHARMACEUTICALS;

(d) the exclusive rights to the manufacturing process used to make the above
THREE PHARMACEUTICALS for the use of manufacturing any other pharmaceutical
compounds or compositions excluding the rights to manufacture any
pharmaceuticals that were previously given to AMAZON BIOTECH INC. and excluding
the rights to manufacture nutritional products that are not marketed as
pharmaceutical drugs; and

(e) any and all other property rights of the Seller, of any kind, character and
description, whether tangible or intangible, which are appurtenant to the
ownership of above THREE PHARMACEUTICALS.

1.2  Purchase Price.
(a) The aggregate purchase price ("Purchase Price") of above THREE
PHARMACEUTICALS shall be seven million (7,000,000) shares of common stock of
Mazal Plant Pharmaceutical, Inc., $.0001 par value ("MPPI shares").

The Purchase Price shall be paid as follows: (a) simultaneously with the
execution of this Agreement, the Purchaser shall issue to Seller seven million
(7,000,000) MPPI shares; (b) the Purchaser agrees to pay to the Seller a royalty
of two cents ($0.02) for each bottle sold of the above THREE PHARMACEUTICALS
that the Purchaser sells for the use of the Sellers processing and manufacturing
technology ("Royalty Payments"). The Purchaser shall pay all Royalty payments to
the Seller on a quarterly basis; and (c) the Purchaser agrees to pay fifty
thousand dollars ($50,000) to the buyer towards the cost of the study conducted
by CRL Clinical Research Laboratories Inc New Jersey 140 patient Double Blind on
the effect of LOCHOL on cholesterol levels.

ARTICLE 2

CLOSINGS

2.1   There has been or shall be delivered, as the case may be, to Purchaser:

(i) Certificates of Title to above THREE PHARMACEUTICALS

(ii) An Assignment to Purchaser of ownership of any patents, copyrights and all
registrations and applications worldwide for above THREE PHARMACEUTICALS;

(iii) All applicable assignments, material consents and other conveyance
documents, including a Bill of Sale and General Assignment Agreement each in
form substantially similar to that attached hereto as Exhibits A and B with
respect to above THREE PHARMACEUTICALS;
<PAGE>

(iv) Express written consents and approvals to the transfer to Purchaser the
rights to above THREE PHARMACEUTICALS as contemplated hereby by all applicable
governmental drug and other regulatory agencies worldwide, and all other
consents or approvals required to effectuate the transaction contemplated
hereby, in form reasonably satisfactory to Purchaser's counsel: and To have and
to hold the same unto Assignee and its assigns forever.

This agreement supercedes all previous agreements made between the "seller" and
the "purchaser"

The Asset Purchase Agreement and all of the terms, conditions, representations,
warranties and covenants therein and the schedules and exhibits thereto, are
incorporated into this General Assignment by reference as if same were set forth
herein.

Any provision of this assignment which may be unenforceable or invalid under any
law shall be ineffective to the extent of such unenforceability or invalidity
without affecting the enforceability or validity of any other provision hereof.

IN WITNESS WHEREOF, Seller has caused these presents to be signed in his name on
this 1st day of December, 2004


Advanced Plant Pharmaceuticals, Inc.                 Mazal Plant Pharmaceuticals

/s/ David Lieberman                                 /s/ Mechael Kanovsky
- ------------------------------------                ----------------------------
David Lieberman                                     Mechael Kanovsky
President                                           President


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>3
<FILENAME>v010547_ex99.txt
<TEXT>
Exhibit 99 - Press Release

       Advanced Plant Pharmaceuticals acquires 99 per cent of Mazal Plant
    Pharmaceuticals Inc. A Company Focused on Developing Three Drugs for FDA
                               Approval Process.

New York, NY-- David Lieberman, CEO of Advanced Plant Pharmaceuticals, Inc.,
(OTCBB: APPI) confirmed today the closing of an asset sale agreement entered
with Mazal Plant Pharmaceuticals Inc., a private Delaware corporation ("Mazal")
whereby in exchange for of 7,000,000 shares of common stock of Mazal, APPI
transferred intellectual property to Mazal relating to three whole plant
pharmaceutical drugs. Mazal presently has 7,050,100 shares of common stock
issued and outstanding. Mazal is focused on the FDA development, testing,
manufacturing and selling of plant pharmaceutical drugs.

APPI focuses on the research and development of whole plant-based products. APPI
has developed three potential whole plant pharmaceutical drugs formulas:

      o     MAHDL designed to lower cholesterol and improve HDL/LDL levels is
            targeted to over 50 Million potential customers in the US and
            Canada.

      o     Leuknil, a Plant-based Pharmaceutical composition designed to treat
            leukemia, and o as well as a plant-based composition designed to
            treat Alzheimer's disease.

APPI has also developed a method for producing these compositions into a drug
form. Mazal initial plans are to apply for an Investigational New Drug from the
FDA and to pursue Phase 2 for the cholesterol drug.

Under the terms of the agreement, APPI has transferred its intellectual property
rights (with exception of rights previously assigned to other entities) to
Mazal, including all patents, trademarks and service marks, labels and
copyrights, and all registrations and applications worldwide related to the
three pharmaceuticals, as well as all technical processes, formulas, recipes
and/or other such information related to development, testing, manufacturing,
packaging and selling of the same.

In exchange, APPI will receive, on a quarterly basis, a royalty on all sales
subject to the terms of the agreement. The Company also acquired 7,000,000
shares of common stock of Mazal.

APPI continues to pursue sales of its nutritional product Lo-Chol targeted for
the nutritional cholesterol market and Sinusol, a OTC homeopathic drug for
treating sinus and allergy ailments

Mazal expects to announce the management team and its web site in the near
future.

Additional corporate information is available on the Company's website,
www.advancedplantpharm.com.
<PAGE>

Forward-Looking Statements:

This release contains forward-looking statements within the meaning and pursuant
to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995
and involve risks and uncertainties that may individually or mutually impact the
matters herein described, including but not limited to product development and
acceptance, manufacturing, competition, regulatory and/or other factors, which
are outside the control of the Company.

Contact:

LC Group
(404) 261-1196


</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
